AnGes MG, Inc. Submits BLA for Naglazyme in Japan.
AnGes established a marketing and distribution agreement with BioMarin Pharmaceutical Inc. in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market.
Naglazyme was approved by the U.S. Food and Drug Administration in May 2005 and by the European Commission in January 2006. As the first drug approved for MPS VI, the FDA and EC have both designated Naglazyme as an orphan drug, conferring seven years of market exclusivity in the United States and 10 years of market exclusivity in the European Union.
In addition, Naglazyme obtained orphan designation in June 2007 from the Ministry of Health, Labour and Welfare in Japan.
JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Aug 15, 2007|
|Previous Article:||Fujifilm's FinePix S5 Pro Receives EISA Award for European Advanced Camera of the Year 2007-2008.|
|Next Article:||"K" Line Honored as Lowe's Inaugural Ocean Carrier of the Year.|